The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

According to the prescribing information, patients treated with Spravato should receive a dose twice a week for the first four weeks. In the following four weeks, the dosing is reduced to once per ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Like many other antidepressants, Spravato works as a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. Where it differs, however, is its ability to travel ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

But it's not entirely known why Spravato works in people with treatment-resistant depression — research just shows that it does. One thing we do know: It acts quickly. "What sets Spravato apart ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

It's called Spravato, made by Johnson and Johnson and it works faster than standard oral antidepressants. Spravato was first approved back in 2019, but at that time, patients had to use it with an ...

The U.S. Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray as a standalone therapy for adults with treatment-resistant depression. The spray, Spravato, first ...

SPRAVATO® is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain.6 The mechanism by which esketamine exerts its antidepressant effect is ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not respond to ...